By Michael Erman NEW YORK (Reuters) – The U.S. Food and Drug Administration will not require companies to submit clinical trial data on COVID-19 vaccines modified to protect against the BA.4 and BA.5 Omicron subvariants in order to authorize those shots, a top FDA official said on Thursday. Dr. Peter …

Source link

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *